title: Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
abstract: This study evaluates the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome (PCOS). During the administration of the pill a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase of the Sex Hormone Binding Globulin (SHBG). The progressive decrease of the total androgenic activity explains the clinical results that have been obtained: at the 36th cycle of therapy acne disappeared in 100% of the cases, seborrea in 76.4% and hirsutism in 75%. Our results underline the need for a continuous administration without interruption of the pill with CPA in patients with clinical hyperandrogenic symptoms.
authors: Department of Obstetrics and Gynecology, University of Brescia, Italy.
authors: L
authors: L
authors: Falsetti
authors: E
authors: E
authors: Galbignani
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy; D000328:Adult; D000410:Alanine Transaminase / Q000032:analysis; D000469:Alkaline Phosphatase / Q000097:blood; D000704:Analysis of Variance; D000726:Androgen Antagonists / Q000494:pharmacology*; D000735:Androstenedione / Q000097:blood; D001219:Aspartate Aminotransferases / Q000032:analysis; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose; D002784:Cholesterol / Q000097:blood; D003277:Contraceptives, Oral, Combined; D003534:Cyproterone / Q000494:pharmacology*; D017373:Cyproterone Acetate; D003687:Dehydroepiandrosterone / Q000097:blood; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000097:blood / Q000494:pharmacology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D010053:Ovary / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism; D011388:Prolactin / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D001786:Blood Glucose; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D012738:Sex Hormone-Binding Globulin; D014280:Triglycerides; D013739:Testosterone; D000735:Androstenedione; D004997:Ethinyl Estradiol; D003687:Dehydroepiandrosterone; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002784:Cholesterol; D003534:Cyproterone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin